Lilly: Augustine Therapeutics Raises EUR 77.7M in Series A Funding
Augustine Therapeutics, a Leuven, Belgium-based biotechnology company focused on developing new therapies through the inhibition of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, raised EUR 77.7M in Series A funding
Read full article »
Lilly is a Massachusetts-based pharmaceutical company that develops, produces and markets pharmaceutical products for healthcare professionals, patients and consumers.
Read more